Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TriPRIL CAR-T cells
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TriPRIL CAR-T cells are autologous T lymphocytes genetically engineered to express a dual-targeted chimeric antigen receptor (CAR) incorporating a trimeric form of the natural ligand APRIL (a proliferation-inducing ligand). This trimeric ligand-based CAR is designed to co-target B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor (TACI) on malignant plasma cells. By targeting both BCMA and TACI, TriPRIL CAR-T cells aim to overcome antigen escape, a common resistance mechanism associated with monospecific BCMA-directed CAR-T therapies. The construct is fused to 4-1BB and CD3ζ intracellular signaling domains to promote T-cell activation and survival. Developed by researchers at Massachusetts General Hospital, TriPRIL CAR-T cells are currently being evaluated in a Phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.
- Other names
- TriPRIL CAR T cellsTriPRIL CARTautologous BCMA/TACI-targeted trimeric APRIL-based CAR T cellstrimeric APRIL CAR T cellstrimeric APRIL CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on TriPRIL CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriPRIL CAR-T cells.